Private Advisor Group LLC Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Private Advisor Group LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 5.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 427,489 shares of the biopharmaceutical company’s stock after selling 25,284 shares during the quarter. Private Advisor Group LLC’s holdings in Pfizer were worth $13,952,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. New England Investment & Retirement Group Inc. purchased a new stake in shares of Pfizer during the 1st quarter valued at approximately $26,000. Lion Street Advisors LLC purchased a new stake in Pfizer in the first quarter valued at approximately $27,000. Benjamin Edwards Inc. raised its position in Pfizer by 49.8% in the first quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 335 shares during the period. Stonebridge Financial Planning Group LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $55,000. Finally, ICW Investment Advisors LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $58,000. 70.28% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:PFE traded down $3.20 on Monday, reaching $34.99. The company’s stock had a trading volume of 2,440,182 shares, compared to its average volume of 21,453,034. The stock’s 50-day moving average is $37.10 and its two-hundred day moving average is $36.82. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $44.56. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78. The stock has a market capitalization of $212.14 billion, a P/E ratio of 12.50, a PEG ratio of 2.79 and a beta of 0.70.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.09. The firm had revenue of $12.03 billion during the quarter, compared to analysts’ expectations of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The firm’s revenue for the quarter was down 8.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.85 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.8 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 8th will be issued a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, May 7th. This represents a $1.52 annualized dividend and a yield of 4.34%. Pfizer’s dividend payout ratio is currently 51.53%.

In related news, EVP Douglas M. Lankler sold 65,000 shares of the stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the completion of the transaction, the executive vice president now directly owns 135,375 shares of the company’s stock, valued at $5,123,943.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Pfizer Inc purchased 312,500 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were purchased at an average cost of $16.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.08% of the company’s stock.

PFE has been the topic of a number of research analyst reports. Barclays boosted their target price on Pfizer from $36.00 to $37.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 29th. Morgan Stanley dropped their price target on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating for the company in a research note on Thursday, April 2nd. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a research note on Thursday, March 19th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target for the company. in a research note on Monday, May 4th. Finally, Standpoint Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Pfizer currently has an average rating of “Hold” and an average price target of $41.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What are the economic characteristics of a bear market?

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.